CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	29.21M
Revenue (ttm)	515,000
Net Income (ttm)	-16.61M
Shares Out	11.45M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,202
Open	2.640
Previous Close	2.650
Day's Range	2.540 - 2.650
52-Week Range	2.540 - 6.750
Beta	0.70
Analysts	Strong Buy
Price Target	12.50 (+390.2%)
Earnings Date	Mar 26, 2025

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN
• Website: https://www.collplant.com

Financial Performance

In 2024, CollPlant Biotechnologies's revenue was $515,000, a decrease of -95.30% compared to the previous year's $10.96 million. Losses were -$16.61 million, 136.6% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CLGN stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 390.20% from the latest price.

Price Target

$12.5

(390.20% upside)

Analyst Consensus: Strong Buy